Журнал кардиореспираторных исследований 2026. №3

Тема статьи

Yurak ishemik kasalligida endotelial va koronar mikrovaskulyar disfunksiyani tashxislash jihatlari (adabiyotlar sharhi) (10-15)

Авторы

Abdullayeva Z.A., Tashkenbaeva E.N., Rasulova D.O., Alimov F.O.

Учреждение

Samarqand davlat tibbiyot universiteti

Аннотация

Koronar mikrovaskulyar disfunksiya (KMD) va endotelial disfunksiya obstruktiv koronar kasalliksiz surunkali koronar sindromli (SKS) bemorlarda (ANOCA/INOCA) miokard ishemiyasining asosiy mexanizmlari bo'lib, bemorlarning 30–50% ida aniqlanadi va yurak-qon tomir xavfini 2–2,5 baravar oshiradi. Maqsad —KMD ning klinik, biomarker va genetik prediktorlarini tizimlashtirish (PubMed, Scopus, eLibrary, 2015– 2026). Klinik prediktorlar, endotelial va yallig'lanish biomarkerlari, yangi markerlar (sTREM2, FT4/FT3, GDF-15), genetik polimorfizmlar (NOS3, ACE, EDN1/PHACTR1) va diagnostika usullari (CFR, IMR, PET) tizimlashtirildi. Bu ma'lumotlarni kompleks baholash SKS diagnostikasini individuallashtirish uchun istiqbolli hisoblanadi.

Ключевые слова

koronar mikrovaskulyar disfunksiya; endotelial disfunksiya; surunkali koronar sindrom; ANOCA; INOCA; biomarkerlar; genetik polimorfizmlar

Литературы

1. Jahon sog‘liqni saqlash tashkiloti. Yurak-qon tomir kasalliklari [Elektron resurs]. – Kirish rejimi: https://www.who.int/ru/healthtopics/cardiovascular-diseases (murojaat sanasi: 10.09.2026). 2. Coronary Microvascular Dysfunction: Insights on Prognosis and Future Perspectives // Reviews in Cardiovascular Medicine. – 2025. – Vol. 26, № 1. DOI: 10.31083/RCM25757. 3. Scarica V., Rinaldi R., Animati F.M. et al. Coronary microvascular dysfunction: pathophysiology, diagnosis, and therapeutic strategies across cardiovascular diseases // EXCLI Journal. – 2025. – Vol. 24. – P. 454–478. DOI: 10.17179/excli2025-8285. 4. Coronary Microvascular Dysfunction: Bridging the Diagnosis–Treatment Divide in Women with INOCA — A Review // PMC. – 2025. – Режим доступа: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12429603/. 5. Новое в ведении пациентов с хроническими коронарными синдромами (краткий обзор рекомендаций ЕОК 2024 г.) // РМЖ. – 2024. 6. Микроваскулярная стенокардия: патогенез, клиника, диагностика и принципы терапии // РМЖ. – 2020. 7. Sex Differences in Coronary Function Test Results in Patient With Angina and Nonobstructive Disease // PMC. – 2021. – Режим доступа: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551605/. 8. Coronary Artery Disease in Women: Sex-Specific Pathophysiology, Risk Factors, Clinical Presentation and Management // Medicina (Kaunas). – 2026. – Vol. 62, № 7. DOI: 10.3390/medicina62071313. 9. Cardiovascular Risk Considerations in Postmenopausal Women: INOCA, CMD, HFpEF // Springer. – 2025/2026. DOI: 10.1007/978-3- 032-18203-6_13. 10. Endothelial microRNAs in INOCA patients with diabetes mellitus // PMC. – 2024. – Режим доступа: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11265336/. 11. Circulating exosomal miR-16-2-3p is associated with coronary microvascular dysfunction in diabetes // PMC. – 2024. – Режим доступа: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10858495/. 12. Толщина эпикардиального жира как предиктор коронарной микрососудистой дисфункции // КиберЛенинка. 13. Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor — markers of endothelial dysfunction in essential hypertension // Journal of Human Hypertension. – 2002. DOI: 10.1038/sj.jhh.1001403. 14. Interrelationship of Multiple Endothelial Dysfunction Biomarkers with Chronic Kidney Disease // PMC. – Режим доступа: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488859/. 15. Zhang H., Che W., Shi K. et al. FT4/FT3 ratio: A novel biomarker predicts coronary microvascular dysfunction in euthyroid INOCA patients // Frontiers in Endocrinology. – 2022. – Vol. 13. DOI: 10.3389/fendo.2022.1021326. 16. Sex-Related Differences in the Prevalence of Classical, Non-Classical Risk Factors and Management of the Chronic Coronary Syndrome // J Clin Med. – 2023. – Vol. 12. – Art. 7320. 17. Galante et al. Coronary microvascular dysfunction in angina and non-obstructive coronary arteries // Kardiologia Polska. – 2025. – Режим доступа: https://journals.viamedica.pl/polish_heart_journal/article/view/105217. 18. Peripheral blood endothelial microparticles (CD144+) as a surrogate marker for coronary microcirculatory dysfunction // PMC. – 2025. – Режим доступа: https://pmc.ncbi.nlm.nih.gov/articles/PMC13456998/. 19. The Relevance of Endothelial Dysfunction Biomarkers: A Systematic Review and Meta-Analysis // PMC. – Режим доступа: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12027490/. 20. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: STABILITY Trial // J Am Heart Assoc. – 2017. DOI: 10.1161/JAHA.116.005077. 21. Clinical and prognostic value of biomarkers in patients with non-obstructive coronary artery disease: systematic review and meta-analysis // PubMed. – 2025. – PMID: 41311056. 22. Women with angina and no obstructive coronary artery disease: IL-6 identifies a cardiometabolic high-risk phenotype // PubMed. – 2025. – PMID: 42668422. 23. MiRNA-34a, miRNA-145, and miRNA-222 Expression, MMPs, TNF-α and VEGF in Patients with Different Phenotypes of CAD // PMC. – 2024. – Режим доступа: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11641108/. 24. Single-Center Analysis of Soluble TREM2 as a Biomarker in Coronary Microvascular Dysfunction // PMC. – 2024/2025. – Режим доступа: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11942759/. 25. Molecular and Functional Significance of Growth Differentiation Factor-15 // PMC. – Режим доступа: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12172221/. 26. Adela R., Banerjee S.K. GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases // Journal of Diabetes Research. – 2015. DOI: 10.1155/2015/490842. 27. Emerging Novel Biomarkers in Acute Coronary Syndrome Management: Insights and Future Directions // ScienceOpen (CVIA). – 2026. DOI: 10.15212/CVIA.2026.0001. 28. Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction // European Heart Journal. – 2020. – Vol. 41, № 34. – P. 3239–3252. 29. Nakayama M., Yasue H., Yoshimura M. et al. T(-786)-C mutation in the 5′-flanking region of the eNOS gene is associated with coronary spasm. 30. Связь полиморфизма генов AGT, ACE, NOS3 с субклиническими изменениями артериальной стенки и факторами риска ССЗ // Journal of Clinical Practice. – 2020. – Т. 11, № 1. 31. Полиморфизм генов преэклампсии и сосудистого тонуса: справочно-аналитический материал. 32. Association of Endothelin-1 (EDN1) rs5370 polymorphism and cardiovascular disease risk // The Egyptian Heart Journal (Springer). – 2025. DOI: 10.1186/s43162-025-00556-0. 33. Genetic susceptibility of five tagSNPs in the EDN1 gene to coronary artery disease in a Chinese Han population // PMC. – Режим доступа: https://pmc.ncbi.nlm.nih.gov/articles/PMC6205642/. 34. Coronary artery spasm: mechanisms, risk factors, and translational strategies for precision management // PMC. – 2025/2026. – Режим доступа: https://pmc.ncbi.nlm.nih.gov/articles/PMC12926906/. 35. Coronary Flow Reserve in Adults: Pathophysiology, Assessment Modalities, Clinical Applications, and Prognostic Significance // Medicina (Kaunas). – 2026. – Vol. 62, № 6. DOI: 10.3390/medicina62061035. 36. Wadhwa, T., Abdullayeva, Z., & Reetika, R. (2026, May). Effect of anti-hypertensives on nitric oxide pathway and duodenal mucosal integrity. In EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (Vol. 56). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY. 37. Абдуллаева, З. А., & Расулова, Д. О. (2026). ИШЕМИЯ МИОКАРДА ПРИ ИНТАКТНЫХ КОРОНАРНЫХ АРТЕРИЯХ: РОЛЬ МИКРОСОСУДИСТОЙ ДИСФУНКЦИИ. In Вестник фундаментальной и клинической медицины (Vol. 6, Issue 26, pp. 397–402). Zenodo.